Patent: 6,936,599
✉ Email this page to a colleague
Summary for Patent: 6,936,599
Title: | Estriol therapy for multiple sclerosis and other autoimmune diseases |
Abstract: | The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, Th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (MS), rheumatoid arthritis (RA), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis. |
Inventor(s): | Voskuhl; Rhonda R. (West Hollywood, CA) |
Assignee: | The Regents of the University of California (Oakland, CA) |
Application Number: | 10/131,834 |
Patent Claims: | see list of patent claims |
Details for Patent 6,936,599
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bayer Healthcare Pharmaceuticals Inc. | BETASERON | interferon beta-1b | For Injection | 103471 | 07/23/1993 | ⤷ Try a Trial | 2021-04-25 |
Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | 05/17/1996 | ⤷ Try a Trial | 2021-04-25 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 05/28/2003 | ⤷ Try a Trial | 2021-04-25 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 02/27/2012 | ⤷ Try a Trial | 2021-04-25 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 03/07/2002 | ⤷ Try a Trial | 2021-04-25 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 12/17/2004 | ⤷ Try a Trial | 2021-04-25 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |